Biocon Limited has informed the Exchange regarding a press release dated November 11, 2025, titled "Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20% EBITDA at Rs 928 crore; Up 29%; PBT (before exceptional items) at Rs 183 Cr, Up 153%".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon reported its Q2FY26 operating revenue at Rs 4,296 crore, registering a 20% year-on-year growth. EBITDA came in at Rs 928 crore, up 29% YoY, indicating operating leverage as profitability grew faster than revenue. Profit before tax (before exceptional items) stood at Rs 183 crore, a sharp jump of 153% YoY, partly aided by a lower base. The results were shared with the exchange via a press release dated November 11, 2025.
Strong topline growth combined with even stronger EBITDA expansion signals improving operational efficiency, which is positive for shareholders. The reference to 'before exceptional items' suggests one-time charges may have impacted reported PBT, so investors should watch for the detailed results for the full picture.